Literature DB >> 27401793

A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.

Noa Bregman1,2, Avner Thaler3,4,5, Anat Mirelman6,2, Rick C Helmich7, Tanya Gurevich6,2, Avi Orr-Urtreger2,8, Karen Marder9, Susan Bressman10, Bastiaan R Bloem7, Nir Giladi6,2.   

Abstract

Mutations in the GBA and LRRK2 genes account for one-third of the prevalence of Parkinson's disease (PD) in Ashkenazi Jews. Non-manifesting carriers (NMC) of these mutations represent a population at risk for future development of PD. PD patient who carry mutations in the GBA gene demonstrates more significant cognitive decline compared to idiopathic PD patients. We assessed cognitive domains using fMRI among NMC of both LRRK2 and GBA mutations to better understand pre-motor cognitive functions in these populations. Twenty-one LRRK2-NMC, 10 GBA-NMC, and 22 non-manifesting non-carriers (NMNC) who participated in this study were evaluated using the standard questionnaires and scanned while performing two separate cognitive tasks; a Stroop interference task and an N-Back working memory task. Cerebral activation patterns were assessed using both whole brain and predefined region of interest (ROI) analysis. Subjects were well matched in all demographic and clinical characteristics. On the Stroop task, in spite of similar behavior, GBA-NMC demonstrated increased task-related activity in the right medial frontal gyrus and reduced task-related activity in the left lingual gyrus compared to both LRRK2-NMC and NMNC. In addition, GBA-NMC had higher activation patterns in the incongruent task compared to NMNC in the left medial frontal gyrus and bilateral precentral gyrus. No whole-brain differences were noted between groups on the N-Back task. Paired cognitive and task-related performance between GBA-NMC, LRRK2-NMC, and NMNC could indicate that the higher activation patterns in the incongruent Stroop condition among GBA-NMC compared to LRRK2-NMC and NMNC may represent a compensatory mechanism that enables adequate cognitive performance.

Entities:  

Keywords:  GBA; LRRK2; N-Back; Stroop; fMRI

Mesh:

Substances:

Year:  2016        PMID: 27401793     DOI: 10.1007/s00429-016-1271-4

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  10 in total

1.  Cognitive deficits and altered cholinergic innervation in young adult male mice carrying a Parkinson's disease Lrrk2G2019S knockin mutation.

Authors:  Ayan Hussein; Alexander Tielemans; Mark G Baxter; Deanna L Benson; George W Huntley
Journal:  Exp Neurol       Date:  2022-06-19       Impact factor: 5.620

2.  Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinson's Disease.

Authors:  Haidar Alzaid; Thomas Ethofer; Markus A Hobert; Bernd Kardatzki; Michael Erb; Walter Maetzler; Daniela Berg
Journal:  Front Aging Neurosci       Date:  2020-08-13       Impact factor: 5.750

3.  Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.

Authors:  Eileen E Moran; Cuiling Wang; Mindy Katz; Laurie Ozelius; Alison Schwartz; Jelena Pavlovic; Roberto A Ortega; Richard B Lipton; Molly E Zimmerman; Rachel Saunders-Pullman
Journal:  Neurobiol Aging       Date:  2017-06-24       Impact factor: 4.673

4.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Authors:  Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek
Journal:  Lancet Neurol       Date:  2019-10-31       Impact factor: 44.182

5.  Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Authors:  Lana M Chahine; Liz Urbe; Chelsea Caspell-Garcia; Dag Aarsland; Roy Alcalay; Paolo Barone; David Burn; Alberto J Espay; Jamie L Hamilton; Keith A Hawkins; Shirley Lasch; James B Leverenz; Irene Litvan; Irene Richard; Andrew Siderowf; Christopher S Coffey; Tanya Simuni; Daniel Weintraub
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

Review 6.  Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.

Authors:  Emilia M Gatto; Gustavo Da Prat; Jose Luis Etcheverry; Guillermo Drelichman; Martin Cesarini
Journal:  Brain Sci       Date:  2019-02-01

7.  Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers.

Authors:  Eileen E Moran; Susan B Bressman; Roberto A Ortega; Deborah Raymond; William C Nichols; Christina A Palmese; Sonya Elango; Matthew Swan; Vicki Shanker; Imali Perera; Cuiling Wang; Molly E Zimmerman; Rachel Saunders-Pullman
Journal:  Front Neurol       Date:  2021-02-26       Impact factor: 4.003

Review 8.  Cognitive Impairment in Genetic Parkinson's Disease.

Authors:  A Planas-Ballvé; D Vilas
Journal:  Parkinsons Dis       Date:  2021-12-30

9.  Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers.

Authors:  Amgad Droby; Moran Artzi; Hedva Lerman; R Matthew Hutchison; Dafna Ben Bashat; Nurit Omer; Tanya Gurevich; Avi Orr-Urtreger; Batsheva Cohen; Jesse M Cedarbaum; Einat Even Sapir; Nir Giladi; Anat Mirelman; Avner Thaler
Journal:  NPJ Parkinsons Dis       Date:  2022-03-03

Review 10.  Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.

Authors:  Massimo Filippi; Roberta Balestrino; Silvia Basaia; Federica Agosta
Journal:  Mov Disord       Date:  2022-05-06       Impact factor: 9.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.